Introduction: Breast cancer is one of the major universal health problems affecting more than two million cases per year. Estrogen receptor alpha (ERα) and P53 are common targets for the treatment of breast cancer and are primarily involved in cell proliferation. The function of p53 protein is regulated by direct binding to MDM2 protein. Therefore, inhibition of p53-MDM2 interaction leads to reactivating p53 activity. Alkaloid compounds generally have potential anticancer effect. Alkaloid compound from Mitragyna speciosa have the potential for anticancer. Methods: The method used is molecular docking with AutoDockTools 1.5.6 program. Predict the properties of physicochemical, pharmacokinetic, and toxicity prediction tests (ADMET) using pkCSM. Results: The results showed that speciophylline, corynoxine A, and corynoxine B have the best values in free binding energy (ΔG) for estrogen receptor (ERα) alpha receptor. Meanwhile, mitraphylline, mitrafoline, and corynoxine B have the best values for protein P53. Predict ADMET using the pkCSM, the alkaloid compound has strong lipophilicity and good permeability so it predicts the ability to penetrate intestinal cell membranes and the skin membrane. Spesiofilin, mitraphylline, and mitrafolin are not expected hepatotoxic. Conclusion: Speciophylline and mitraphylline have potential as anticancer drugs through the inhibitory of estrogen receptor alpha and MDM2 reseptor.

Background: The incidence of hepatitis in children has grown from the normal number of hepatitis cases since January 2022, and it will continue to rise since the etiology and pathophysiology are unknown. This case is distinct from those caused by the hepatitis A, B, C, D, and E viruses. Glycyrrhiza glabra L. is a medicinal herb that has long been used in medicine to treat respiratory, digestive, and immune system problems, but it is also known to have an inhibitory impact on the virus. Coronavirus-associated acute respiratory syndrome, hepatitis, herpes simplex virus, influenza virus. Objective: This article will look at Glycyrrhiza glabra L.'s antihepatitis and hepatoprotective properties. Methods: The Pubmed, Sage Journal, and Sciencedirect databases were searched using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards and the keywords "Glycyrrhiza glabra for hepatitis." The inclusion and exclusion criteria were followed. Results: From the search results, 17 publications were discovered that explain how Glycyrrhiza glabra L. can operate as an antihepatitis agent through anti-inflammatory, antiapoptotic, and hepatoprotective mechanisms. Conclusion: Glycyrrhiza glabra L. can be used as an anti-hepatitis and hepatoprotective in children at doses ranging from 240-480mg/kg/day.